This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.
A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Global leader in APC-targeted immunotherapy technology
NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~$700M)
Proprietary immunotherapies targeting antigens to Antigen-Presenting Cell (APC) and generating strong CD8 killer T cell responses correlated with clinical responses in solid tumors
Modular, versatile platform
Easily incorporate new antigens and adapt to new diseases across oncology, infectious diseases and autoimmunity
Rapidly advancing wholly owned lead asset, VB10.16, immunotherapy for HPV16+ cancers
Final data from phase 2 VB-C-02- unprecedented long lasting survival benefit in advanced cervical cancer
Potentially registrational study in advanced cervical cancer to initiate 2023
Dose escalation study with KEYTRUDA®1 in head and neck cancer to initiate 1H2023
Strategic partnerships to advance clinical programs and commercialize assets worldwide2
Well-capitalized with a cash position of $186m at March 31, 2023
Note: KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Note: Genentech has an exclusive license to VB10.NEO. Collaboration and license to 5 programs with Regeneron. Collaboration and license with Adaptive Biotechnologies on SARS-CoV-2 T cell vaccine. Roche supplies atezolizumab; . Merck (MSD) supplies pembrolizumab
Nykode announced collaboration with the gynecologic study group GOG Foundation to conduct the planned VB-C-04 trial in advanced cervical cancer.
Presented additional immunogenicity data from the Phase 1/2a clinical trial of VB10.NEO, Nykode's individualized neoantigen cancer vaccine, presented at the 2023 American Association for Cancer
Research Annual Meeting.
After March 31, 2023:
Nykode announced positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer.
Nykode Therapeutics AS published this content on 12 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 May 2023 10:02:01 UTC.
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeuticsâ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
NYKODE THERAPEUTICS 
